An 8-week, open-label, single-center trial evaluated the efficacy and safety of high-dose topical calcitriol ointment (20 ug/g) once daily in 37 patients with facial psoriatic lesions. Efficacy was evaluated by the facial Psoriasis Area and Severity Index (fPASI) and Physician's Global Assessment (PGA) at weeks 2, 4 and 8 and by Subjective Global Assessment (SGA) at the end of the study. In the 33 patients who completed the study, fPASI scores fell from a mean of 33 at baseline to a mean of 3.88 at week 8 (P < 0.01). On the PGA, excellent, good and fair improvement was seen in 18.2, 48.5 and 12.1% of patients, respectively. On the ...